Interpace Biosciences , Inc. (NASDAQ: IDXG) (“Interpace”) a leader
in enabling personalized medicine, is pleased to announce today
that Ron Rocca, President & CEO of Exagen, Inc. (NASDAQ: XGN)
has been appointed to the Interpace Board of Directors. Ron has
significant experience as a senior executive at companies which
develop and market high value, proprietary tests. In addition to
serving as CEO of Exagen since 2011, Mr. Rocca served as VP of
Sales & Marketing and General Manager of Prometheus
Laboratories from 2005 to 2011.
According to Steve Sullivan, Interpace’s
Chairman of the Board, “We are very pleased to welcome Mr. Rocca to
the Board of Interpace. His impressive executive experience will
undoubtedly bring considerable value as we approach important
milestones, seek to accelerate growth and position ourselves as a
leader in personalized medicine.”
We are also announcing the retirement of our
Chief Financial Officer and Treasurer, James Early, and the
appointment of Fred Knechtel to succeed Jim. Mr. Early has been
working at Interpace since 2016.
Previously, Mr. Knechtel held numerous CFO roles
with companies that range in size from $100 million to $5 billion
in revenue. As a public and private equity-backed company CFO, he
has improved operational performance, transformed business
processes, led M&A activities, and coordinated successful fund
raisings and refinancing efforts. Most recently at GENEWIZ, a
leading global genomics service company that provides DNA
sequencing, gene synthesis, next generation sequencing and
bioinformatics services, Fred led all finance/accounting, M&A
and corporate finance activities. .
“We sincerely thank Jim for his service and
assistance in transforming Interpace from a molecular diagnostic
testing and service company into a broader based biosciences
business including biopharma services that has been capitalized
with two well-known private equity firms.” said Jack Stover, CEO of
Interpace. Jim will assist in the transition and has also agreed to
be available to assist on special projects. "We wish him all the
best in his retirement," concluded Stover.
“We welcome Fred who will lead all aspects of
Interpace’s financial activities going forward. We anticipate
utilizing Fred’s previous life sciences experience and expertise in
working with private equity firms and public companies to establish
strong organizational discipline and controls as we continue to
grow, improve profitability and drive positive cash flow,” added
In addition, Interpace is announcing the hiring
of Jeff Salzman as Vice President of Managed Care and Payer
Relations. “Jeff has a terrific background with companies such as
Quest Diagnostics, Monogram Biosciences, Vermillion and most
recently CareDx where he helped establish and expand coverage for
various lab tests, launched multiple genomic assays and negotiated
in network contracts with national and regional payors,” added Mr.
About Interpace Biosciences
Interspace Biosciences is a leader in enabling
personalized medicine, offering specialized services along the
therapeutic value chain from early diagnosis and prognostic
planning to targeted therapeutic applications.
Interpace Diagnostics is a fully integrated
commercial and bioinformatics business unit that provides
clinically useful molecular diagnostic tests, bioinformatics and
pathology services for evaluating risk of cancer by leveraging the
latest technology in personalized medicine for improved patient
diagnosis and management. Interpace has four commercialized
molecular tests and one test in a clinical evaluation process
(CEP): PancraGEN® for the diagnosis and prognosis of pancreatic
cancer from pancreatic cysts; ThyGeNEXT® for the diagnosis of
thyroid cancer from thyroid nodules utilizing a next generation
sequencing assay; ThyraMIR® for the diagnosis of thyroid cancer
from thyroid nodules utilizing a proprietary gene expression assay;
and RespriDX® that differentiates lung cancer of primary vs.
metastatic origin. In addition, BarreGEN® for Barrett’s Esophagus,
is currently in a clinical evaluation program whereby we gather
information from physicians using BarreGEN® to assist us in
positioning the product for full launch, partnering and potentially
supporting reimbursement with payers.
Interpace Pharma Solutions provides
pharmacogenomics testing, genotyping, biorepository and other
customized services to the pharmaceutical and biotech industries
while also advancing personalized medicine by partnering with
pharmaceutical, academic, and technology leaders to effectively
integrate pharmacogenomics into their drug development and clinical
trial programs with the goals of delivering safer, more effective
drugs to market more quickly, and improving patient care.
For more information, please visit Interpace Biosciences’
website at www.interpace.com.
This press release contains forward-looking
statements within the meaning of Section 27A of the Securities Act
of 1933, Section 21E of the Securities Exchange Act of 1934 and the
Private Securities Litigation Reform Act of 1995, relating to the
Company's future financial and operating performance. The Company
has attempted to identify forward looking statements by terminology
including "believes," "estimates," "anticipates," "expects,"
"plans," "projects," "intends," "potential," "may," "could,"
"might," "will," "should," "approximately" or other words that
convey uncertainty of future events or outcomes to identify these
forward-looking statements. These statements are based on current
expectations, assumptions and uncertainties involving judgments
about, among other things, future economic, competitive and market
conditions and future business decisions, all of which are
difficult or impossible to predict accurately and many of which are
beyond the Company's control. These statements also involve known
and unknown risks, uncertainties and other factors that may cause
the Company's actual results to be materially different from those
expressed or implied by any forward-looking statement.
Additionally, all forward-looking statements are subject to the
“Risk Factors” detailed from time to time in the Company's most
recent Annual Report on Form 10-K, Quarterly Reports on Form 10Q
and Current Report on Form 8-K filed September 20, 2019. Because of
these and other risks, uncertainties and assumptions, undue
reliance should not be placed on these forward-looking statements.
In addition, these statements speak only as of the date of this
press release and, except as may be required by law, the Company
undertakes no obligation to revise or update publicly any
forward-looking statements for any reason.
Investor Relations - Edison Group Joseph Green (646) 653-7030;
Interpace Biosciences (NASDAQ:IDXG)
Historical Stock Chart
From Jul 2020 to Aug 2020
Interpace Biosciences (NASDAQ:IDXG)
Historical Stock Chart
From Aug 2019 to Aug 2020